Appropriate management of hypertension reduces the risk for cardiovascular disease, renal disease, cerebrovascular disease, and death (3) (4) (5) (6) . However, determining the most appropriate BP targets, particularly for adults aged 60 years or older, has been controversial. Debate about the goal for systolic BP (SBP) among adults treated for hypertension has intensified, especially in light of recent recommendations (7) . In addition, when selecting BP targets for adults aged 60 years or older, clinicians need to consider comorbid conditions that could affect treatment choice. Treatments for hypertension include lifestyle modifications, such as weight loss, dietary modification, and increased physical activity, and antihypertensive medications, which commonly include thiazide-type diuretics, angiotensinconverting enzyme inhibitors (ACEIs), angiotensinreceptor blockers (ARBs), calcium-channel blockers, and ␤-blockers.
GUIDELINE FOCUS AND TARGET POPULATION
The purpose of this American College of Physicians (ACP) and American Academy of Family Physicians (AAFP) joint guideline is to present evidence-based recommendations on the benefits and harms of higher (<150 mm Hg) versus lower (≤140 mm Hg) SBP targets for the treatment of hypertension in adults aged 60 years or older. The target audience for this guideline includes all clinicians, and the target patient population includes adults aged 60 years or older with hypertension. These recommendations are based on a background evidence review (8) and systematic review sponsored by the U.S. Department of Veterans Affairs (VA) (9) .
METHODS

Systematic Review of the Evidence
The evidence review was conducted by the Portland VA Health Care System Evidence-based Synthesis Program. The summary of methods for the evidence review can be found in the Appendix (available at Annals.org). Additional details are included in the accompanying background evidence review (8) and the full evidence report (9) .
Grading the Evidence and Developing Recommendations
This guideline was jointly developed by ACP's Clinical Guidelines Committee and representatives from AAFP according to ACP's guideline development process, details of which can be found in the methods paper (10) . The committee used the evidence tables in the accompanying systematic review (8) and full report (9) when reporting the evidence and graded the recommendations using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) method (Table) .
Peer Review
The VA evidence review was peer reviewed and posted on the VA Web site for public comments, and the published review article was peer reviewed through the journal. The guideline had a peer-review process through the journal and was posted online for comments from ACP Regents and Governors, who represent physician members at the national and international level. The guideline was also reviewed by members of AAFP's Commission on Health of the Public and Science.
BENEFITS OF TREATING HIGHER VERSUS LOWER BP TARGETS IN OLDER ADULTS
Across all trials, treating high BP in older adults was beneficial. However, most of the evidence came from studies of patients with moderate or severe hypertension (SBP >160 mm Hg) at baseline and, with treatment, achieved SBP targets greater than 140 mm Hg.
Differing BP Targets
Moderate-quality evidence showed a reduction in all-cause mortality among patients with a baseline SBP of 160 mm Hg or greater who achieved a target SBP of less than 150 mm Hg, although the reductions did not quite reach statistical significance (relative risk [ (11-13, 20, 22, 23) . Many of these studies, however, did not achieve the targeted BP, and there was little difference in BP between the intensive treatment and control groups. Therefore, these studies may not have been able to detect differences in clinical outcomes.
A subgroup analysis compared studies that achieved lower SBP targets (<140 mm Hg) with those that achieved higher SBP targets (≥140 mm Hg) (11-13, (26, 27) . Heterogeneity for this analysis was low.
Differing BP Targets Based on Age
Low-quality evidence showed similar effects across different age groups (12-14, 16, 18 -20, 22, 24, 26, 28, 29) . A subgroup analysis of SPRINT (Systolic Blood Pressure Intervention Trial) that was not included in the evidence review showed that patients aged 75 years or older had lower all-cause mortality and nonstatistically significantly lower cardiovascular mortality, morbidity, and incidence of stroke with treatment to SBP targets less than 120 mm Hg compared with SBP targets less than 140 mm Hg (30) .
Differing BP Targets Based on Multiple Chronic Conditions
No trials assessed the effect of comorbidity on the benefits of more aggressive BP treatment. Low-quality evidence from subgroup analyses showed greater absolute benefit from more intensive BP treatment in patients with high cardiovascular risk (22, 29 -31) . However, patients with a high comorbidity burden were probably not included in the overall group of studies (8) . Of the 21 trials included in the review, 14 excluded patients with heart failure, 11 excluded those with recent cardiovascular events, 17 excluded those with abnormal renal function, 12 excluded those with cancer or other life-limiting illness, 15 had criteria that would implicitly or explicitly exclude those with dementia or diminished functional status, and 7 excluded either all diabetic patients or those who required insulin. Although findings from ACCORD (Action to Control Cardiovascular Risk in Diabetes), which limited enrollment to patients with type 2 diabetes, found no reduction in mortality or major cardiovascular events with more intensive treatment, a subgroup analysis of 7 studies (12, 14, 18 -20, 28, 29) in diabetic patients suggested that they were at least as likely to benefit from BP-lowering treatment. This is probably related to the higher frequency of cardiovascular events seen in these patients.
Treatment Effects According to Diastolic BP
Evidence was insufficient to determine the benefit of treating diastolic hypertension in the absence of systolic hypertension. Most trials assessed treatment outcomes based on SBP, and no trials included patients with a mean diastolic BP (DBP) greater than 90 mm Hg and a mean SBP less than 140 mm Hg.
HARMS OF HIGHER VERSUS LOWER BP TARGETS IN OLDER ADULTS
Studies showed mixed findings for withdrawal due to adverse events. Treatment to lower BP targets increased withdrawals due to adverse events in 4 out of 10 trials (RR, 44% to 100%); cough and hypotension were the most frequently reported adverse events (13, 15, 17, 18, 20, 24, 27, 29, 31, 32) . Low-quality evidence showed an increased risk for syncope associated with treatment to lower BP targets (achieved SBP range, 121.5 to 143 mm Hg) (RR, 1.52 [CI, 1.22 to 2.07]) (18, 23, 28) . Low-quality evidence showed no difference in renal outcomes (including end-stage renal disease) for treatment to higher versus lower BP targets (13, 15, 16, 18, 20, 22-25, 28, 29, 32-34) . Moderate-quality evidence showed no differences between treatment to higher versus lower BP targets in the degree of cognitive decline or dementia (18, 27, 35-39), fractures (40, 41) , or quality of life (17, (42) (43) (44) . Low-quality evidence showed no difference for treatment to higher versus lower BP targets on functional status (42) or the risk for falls (23, 40) . A subgroup analysis of SPRINT showed a nonstatistically significant increase in the rate of serious adverse events, hypotension, syncope, electrolyte abnormalities, or acute kidney injury in patients aged 75 years or older who were treated to SBP targets less than 120 mm Hg versus SBP targets less than 140 mm Hg (28) .
Although electrolyte disturbances are a common adverse effect of hypertension treatment in clinical practice, data were not presented on these abnormalities in the evidence review. Drugs to treat hypertension have well-known adverse effects, including hypokalemia, hyperkalemia, hyponatremia, hypotension, dizziness, headache, edema, erectile dysfunction, and cough.
Effect of Age
Low-quality evidence showed no difference in adverse events, including unsteadiness, dizziness, and renal failure, in patients younger or older than 75 years (13, 23, 28).
Effect of Multiple Chronic Conditions
No trials assessed the effect of comorbid conditions on harms.
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RECOMMENDATIONS
The Figure summarizes High-quality evidence showed that treating hypertension in older adults to moderate targets (<150/90 mm Hg) reduces stroke (ARR, 0.92) and cardiac events (ARR, 0.72). Moderate-quality evidence showed a possible reduction in mortality, however, the results did not quite achieve statistical significance (RR, 0.93 [CI, 0.85 to 1.00]). Most benefits apply to all adults regardless of whether they have diabetes. We rated the overall evidence as high because effects were favorable across outcomes and the reduction in mortality was nearly statistically significant. The most consistent and greatest absolute benefit was shown in trials with a higher mean SBP at baseline (>160 mm Hg). Any additional benefit from aggressive BP control is small, with a lower magnitude of benefit and inconsistent results across outcomes.
Although this guideline did not specifically address pharmacologic versus nonpharmacologic treatments for hypertension, several nonpharmacologic treatment strategies are available for consideration. Effective nonpharmacologic options for reducing BP include such lifestyle modifications as weight loss, such dietary changes as the DASH (Dietary Approaches to Stop Hypertension) diet, and an increase in physical activity. Nonpharmacologic options are typically associated with fewer side effects than pharmacologic therapies and have other positive effects; ideally, they are included as the first therapy or used concurrently with drug therapy for most patients with hypertension. Effective pharmacologic options include antihypertensive medications, such as thiazide-type diuretics (adverse effects include electrolyte disturbances, gastrointestinal discomfort, rashes and other allergic reactions, sexual dysfunction in men, photosensitivity reactions, and orthostatic hypotension), ACEIs (adverse effects include cough and hyperkalemia), ARBs (adverse effects include dizziness, cough, and hyperkalemia), calcium-channel blockers (adverse effects include dizziness, headache, edema, and constipation), and ␤-blockers (adverse effects include fatigue and sexual dysfunction).
Most of the included studies measured seated BP after 5 minutes of rest and used multiple readings. Clinicians should ensure that they are accurately measuring BP before beginning or changing treatment of hypertension. Assessment may include multiple measurements in clinical settings (for example, 2 to 3 readings separated by 1 minute in a seated patient who is resting alone in a room) or ambulatory or home monitoring (45) . 
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stroke, at high-risk for cardiovascular disease, and with a baseline SBP of less than 140 mm Hg significantly reduced fatal and nonfatal cardiovascular events and all-cause mortality. In contrast, ACCORD (40) included only adults with type 2 diabetes at high cardiovascular risk and found no statistically significant reduction in the primary composite outcome of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular events (RR, 0.94 [CI, 0.80 to 1.11] ). This study did find a reduction in stroke events (RR, 0.58 [CI, 0.39 to 0.88]), but there were more serious adverse events associated with an SBP target of less than 120 mm Hg versus less than 140 mm Hg. In light of the low-quality evidence of no statistically significant reduction in mortality, cardiac events, or stroke from pooled estimates from all studies, but benefit shown by SPRINT, as well as the known harms, burden, and costs of more intensive pharmacological therapy, an individualized assessment is important to evaluate the benefit of lower blood pressure targets relative to harms in patients age 60 years and older.
AREAS OF INCONCLUSIVE EVIDENCE Treatment of Patients With Multiple Chronic Conditions
No trials assessed the relationship between multiple comorbid conditions and the benefits and harms of treating BP to different targets. Patients with a high comorbidity burden were probably not included in the overall group of studies. Many studies excluded patients with various comorbid conditions, such as diabetes, insulin use, recent coronary events, heart failure, or chronic kidney disease, and most studies had criteria that would implicitly or explicitly exclude those with dementia or diminished functional status.
Treating According to DBP
Evidence was insufficient for targeting treatment according to DBP.
MULTIPLE CHRONIC CONDITIONS: CLINICAL CONSIDERATIONS FOR ADULTS AGED 60 YEARS OR OLDER
Individual assessment of benefits and harms is particularly important in adults aged 60 years or older with multiple chronic conditions, several medications, or frailty. These patients might theoretically benefit from more aggressive BP treatment because of higher cardiovascular risks. However, they are more likely to be susceptible to serious harm from higher rates of syncope and hypotension, which were seen in some trials. Moreover, the absolute benefits of more aggressive BP treatment in elderly persons, those with multimorbidity, or those who are frail are not well-known, given limitations of the trials. These patients often receive multiple medications and are on drug regimens that are difficult to manage and increase the cost and risk for drug interactions. Indeed, most trials had exclusion criteria that implicitly or explicitly excluded patients who had dementia or diminished functional status. Few trials were available to compare patients with and without diabetes, which made drawing conclusions about relative treatment effects in these populations difficult. Whether the difference in results between SPRINT and ACCORD was because of diabetes status is unclear, but it is reasonable to rationalize that the benefits observed with the lower targets achieved in SPRINT most closely apply to patient populations without diabetes.
HIGH-VALUE CARE
Most patients aged 60 years or older with an SBP of 150 mm Hg or greater who receive antihypertensive medications will have benefit with acceptable harms and costs from treatment to a BP target of less than 150/90 mm Hg. Although some benefit is achieved by aiming for lower BP targets, in some patients most benefit occurs with acceptable harms and costs in the pharmacologic treatment of patients who have an SBP of 150 mm Hg or greater. When prescribing drug therapy, clinicians should select generic formulations over brand-name drugs, which have similar efficacy, reduced cost, and therefore better adherence (46) . Clinicians should consider the patient's treatment burden when deciding on treatment options. Studies have correlated multiple doses of hypertensive medications with poorer medication adherence (47, 48) . The balance of benefits and harms identified in our evidence report is based in part on rigorous and accurate assessment of BP. Some patients may have falsely elevated readings in clinical settings (known as "white-coat hypertension"). Therefore, it is important to ensure accurate BP measurement before initiating or changing treatment of hypertension. The most accurate measurements come from multiple BP measurements made over time. Note: Clinical practice guidelines are "guides" only and may not apply to all patients and all clinical situations. Thus, they are not intended to override clinicians' judgment. All ACP clinical practice guidelines are considered automatically withdrawn or invalid 5 years after publication or once an update has been issued.
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Requests for Single
Search Strategy
The reviewers searched EMBASE and the Cochrane Database of Systematic Reviews from database inception through January 2015, MEDLINE through September 2016, and ClinicalTrials.gov to identify studies that were in progress or unpublished. Observational studies were excluded from analysis of such health outcomes as mortality, stroke, and cardiovascular events. For additional information, including inclusion and exclusion criteria, refer to the accompanying article (8) and full report (9) .
Meta-analysis and Individual-Patient Data Meta-analysis
The reviewers conducted a meta-analysis on studylevel data using the random-effects model. They also conducted individual-patient data meta-analysis to assess treatment according to age subgroups.
Quality Assessment
The quality of studies was assessed using the Cochrane risk-of-bias tool (49). The evidence reviewers graded the quality of evidence using the Agency for Healthcare Research and Quality system (50).
Population
Adults aged 60 years or older with a diagnosis of hypertension were studied.
Interventions Evaluated
The interventions evaluated included treatment to higher (<150 mm Hg) versus lower (≤140 mm Hg) SBP targets.
Comparators
The comparator was less intensive BP treatment.
Outcomes
Evaluated outcomes included all-cause mortality; cardiac events (myocardial infarction and sudden cardiac death); morbidity and mortality related to stroke; and harms, including cognitive impairment, quality of life, falls, fractures, syncope, functional status, hypotension, acute kidney injury (defined as the doubling of serum creatinine or need for renal replacement therapy), medication burden, and withdrawal due to adverse events.
Timing
Outcomes were assessed in the long-term (>6 months) for KQs 1, 2, and 3 and any time frame for KQs 4 and 5.
Study Design
Controlled study designs (randomized, controlled trials and nonrandomized, controlled trials) (KQs 1, 2, 3, 4 and 5) and cohort studies (KQs 4 and 5) were included. Case reports; case series; randomized, controlled trials with less than 6-month follow-up; and controlled before-after studies were excluded.
Peer Review
The VA evidence review was sent to invited peer reviewers and posted on the VA Web site for public comments, and the published review article was peer reviewed through the journal. The guideline had a peer-review process through the journal and was posted online for comments from ACP Regents and Governors, who represent physician members at the national level. It was also reviewed by members of AAFP's Commission on Health of the Public and Science. Recommendation 1 now reads as follows: "ACP and AAFP recommend that clinicians initiate treatment in adults aged 60 years or older with systolic blood pressure persistently at or above 150 mm Hg to achieve a target systolic blood pressure of less than 150 mm Hg to reduce the risk for stroke, cardiac events, and possibly mortality. (Grade: strong recommendation, high-quality evidence). ACP and AAFP recommend that clinicians select the treatment goals for adults aged 60 years or older based on a periodic discussion of the benefits and harms of specific blood pressure targets with the patient." The original wording of the first sentence of that recommendation was ". . . to achieve a target systolic blood pressure of less than 150 mm Hg to reduce the risk for mortality, stroke, and cardiac events."
Recommendation 3 now reads as follows: "ACP and AAFP recommend that clinicians consider initiating or intensifying pharmacologic treatment in some adults aged 60 years or older at high cardiovascular risk, based on individualized assessment, to achieve a target systolic blood pressure of less than 140 mm Hg. (Grade: weak recommendation, low-quality evidence). ACP and AAFP recommend that clinicians select the treatment goals for adults aged 60 years or older based on a periodic discussion of the benefits and harms of specific blood pressure targets with the patient." The original wording of that recommendation was "ACP and AAFP recommend that clinicians consider initiating or intensifying pharmacologic treatment in some adults aged 60 years or older at high cardiovascular risk, based on individualized assessment, to achieve a target systolic blood pressure of less than 140 mm Hg to reduce the risk for stroke or cardiac events."
The first 2 paragraphs under the heading, "Differing BP Targets," now read as follows: "Moderate-quality evidence showed a reduction in all-cause mortality among patients with a baseline SBP of 160 (11-13, 20, 22, 23) . Many of these studies, however, did not achieve the targeted BP, and there was little difference in BP between the intensive treatment and control groups. Therefore, these studies may not have been able to detect differences in clinical outcomes. The original wording of the first 2 paragraphs under that heading was "High-quality evidence showed reductions in all- (11-13, 20, 22, 23) . For studies with lower BP targets, moderate-quality evidence showed a reduced risk for stroke (RR, 0.79 [CI, 0.59 to 0.99]; ARR, 0.49) compared with higher BP targets (11-13, 20, 22, 23) . Many of these studies, however, did not achieve the targeted BP, and there was little difference between the intensive treatment and control groups. Therefore, these studies may not have been able to detect differences in clinical outcomes."
In the Figure, the benefits statements reads as follows: "Incidence of stroke and cardiac events were reduced with treatment to <150 mm Hg' and 'Treating to 140 mm Hg did not have additional benefit". The original wording was "Mortality, incidence of stroke, and cardiac events were all reduced with treatment" and "Treating to a lower BP target did noti further reduce mortality, quality of life, or functional status, but it did reduce the incidence of stroke and cardiac events".
The first paragraph under Recommendation 1 on page 433 now reads as follows: "High-quality evidence showed that treating hypertension in older adults to moderate targets (<150/90 mm Hg) reduces stroke (ARR, 0.92) and cardiac events (ARR, 0.72). Moderate-quality evidence showed a possible reduction in mortality, however, the results did not quite achieve statistical significance (RR, 0.93 [CI, 0.85 to 1.00]). Most benefits apply to all adults regardless of whether they have diabetes. We rated the overall evidence as high because effects were favorable across outcomes and the reduction in mortality was nearly statistically significant. The most consistent and greatest absolute benefit was shown in trials with a higher mean SBP at baseline (>160 mm Hg). Any additional benefit from aggressive BP control is small, with a lower magnitude of benefit and inconsistent results across outcomes." The original wording of that paragraph was "High-quality evidence showed that treating hypertension in older adults to moderate targets (<150/90 mm Hg) reduces mortality (ARR, 1.64), stroke (ARR, 1.13), and cardiac events (ARR, 1.25). Most benefits apply to such adults regardless of whether they have diabetes. The most consistent and greatest absolute benefit was shown in trials with a higher mean SBP at baseline (>160 mm Hg). Any additional benefit from aggressive BP control is small, with a lower magnitude of benefit and inconsistent results across outcomes."
The first paragraph under Recommendation 3 on page 433 now reads: "An SBP target of less than 140 mm Hg is a reasonable goal for some patients with increased cardiovascular risk. While pooled estimates of all studies demonstrated no statisticaly significant reductions in mortality, cardiac events, or stroke a single large, high quality study (SPRINT) did find benefits across all outcomes in high risk individuals without diabetes. The target depends on many factors unique to each patient, including comorbidity, medication burden, risk for adverse events, and cost. Clinicians should individually
